Full Press Release Details
StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries
Whole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologies
SAN DIEGO,June 8, 2026/PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth of coverage and resolution to redefine what researchers can detect with spatial transcriptomics. StrataMap Spatial, previously called the Illumina Spatial Solution, is an end-to-end sequencing-based research solution to uncover spatial insights. Spatial transcriptomics is already a critical tool in developmental biology, neuroscience, and oncology research. StrataMap Spatial expands researchers' ability to map tissue structure, reveal tissue function, track tumor progression, and identify novel drug targets for precision medicine.